A5089695678- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Cancer Risks and Factors
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Global Cancer Incidence and Screening
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Estrogen and related hormone effects
- Cancer, Lipids, and Metabolism
- Immune Cell Function and Interaction
- Cancer-related Molecular Pathways
- Cancer, Hypoxia, and Metabolism
- Gastric Cancer Management and Outcomes
- Cancer Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Ferroptosis and cancer prognosis
- Hip and Femur Fractures
- Circular RNAs in diseases
- Breast Lesions and Carcinomas
- Pelvic and Acetabular Injuries
- Bone fractures and treatments
Hebei Medical University
2014-2024
Fourth Hospital of Hebei Medical University
2014-2024
First Affiliated Hospital of Hebei Medical University
2019-2024
Chinese Society of Clinical Oncology
2023
Collaborative Group (United States)
2023
Hospital of Hebei Province
2020-2023
Luoyang Institute of Science and Technology
2022
Breast Center
2021
Chinese PLA General Hospital
2020
Qingdao University
2020
Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy of pyrotinib versus lapatinib, both combination with capecitabine, women human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer open-label, multicenter, randomized II study.Chinese patients HER2-positive relapsed or previously treated taxanes, anthracyclines, and/or trastuzumab were assigned (1:1) to receive 400...
1022 Background: Currently, there are no standard ≥3 line regimens recommended for HER2-positive (IHC 3+, or IHC 2+/FISH+) advanced metastatic breast cancer, and HER2-targeting treatment HER2-low expressing 2+/FISH-, 1+) population. RC48-ADC is an innovative antibody-drug conjugate with a cleavable linker potent microtubule inhibitor payload MMAE that has bystanding effect in tumor cell killing. Methods: C001 CANCER (NCT02881138) was dose-escalation phase I study (0.5, 1.0, 1.5, 2.0, 2.5...
Standard adjuvant chemotherapy for triple-negative breast cancer (TNBC) includes a taxane and an anthracycline. Concomitant capecitabine may be beneficial, but robust data to support this are lacking. The efficacy safety of the addition into TNBC treatment regimen was evaluated.This randomized, open-label, phase III trial conducted in China. Eligible female patients with early after definitive surgery were randomly assigned (1:1) either (3 cycles docetaxel followed by 3 capecitabine,...
Pyrotinib (an irreversible pan-ErbB inhibitor) plus capecitabine has survival benefits and acceptable tolerability in patients with HER2-positive metastatic breast cancer. We further assessed addition of pyrotinib to trastuzumab docetaxel the neoadjuvant setting. In this multicenter, double-blind, phase 3 study (PHEDRA), treatment-naive women early or locally advanced cancer were randomly assigned (1:1) receive four cycles oral placebo (400 mg) once daily, intravenous (8 mg/kg loading dose,...
Abstract Background Disitamab vedotin (DV; RC48‐ADC) is an antibody‐drug conjugate comprising a human epidermal growth factor receptor 2 (HER2)‐directed antibody, linker and monomethyl auristatin E. Preclinical studies have shown that DV demonstrated potent antitumor activity in preclinical models of breast, gastric, ovarian cancers with different levels HER2 expression. In this pooled analysis, we report the safety efficacy patients HER2‐overexpression HER2‐low advanced breast cancer (ABC)....
TP53 gene is mutated in approximately 80% of triple-negative breast cancer (TNBC). However, the prognostic significance immunohistochemical (IHC)-detected p53 protein expression remains controversial TNBC. In this study, we retrospectively analyzed association between IHC-detected and prognosis a cohort 278 patients with stage I-III invasive ductal carcinoma (IDC), who received surgery at department Fourth Hospital Hebei Medical University from 2010-01 to 2012-12. We found positive ratio IDC...
Breast cancer treatment has profoundly improved in China recently. However, trends disparities and transitions of early-stage between the US are not well known.
Abstract Currently approved HER2-targeting antibody-drug conjugates (ADCs) for HER2-positive breast cancer (BC) are associated with safety concerns. In this multicenter, single-arm, dose-escalation (phase 1a) and dose-expansion 1b) phase 1 trial (NCT03944499), patients HER2-expressing advanced solid tumors received FS-1502 (an anti-HER2 ADC) a 3 + design in 1a; metastatic BC at the recommended 2 dose (RP2D) 1b. The primary end points were dose-limiting toxicities (DLTs), maximum tolerated...
The purpose of this study was to compare the clinical outcomes elderly patients undergoing surgery for treatment unstable trochanteric fractures receiving either proximal femoral nails anti-rotation-Asia (PFNA-IIs) or InterTan (ITs). Between January 1, 2012, and June 31, 2015, 168 with intertrochanteric femur enrolled in study. only intervention ITs PFNA-IIs fractures. Follow-up at 3, 6, 12 months postoperatively yearly thereafter. Intraoperative variables postoperative complications were...
BackgroundCancer patients had been profoundly affected by the outbreak of COVID-19 especially after quarantine restrictions in China. We aimed to explore treatment changes and delays early breast cancer (EBC) during first quarter 2020.MethodsWe did this retrospective, multicentre, cohort study at 97 centres EBC who received regardless preoperative therapy, surgery or postoperative therapy 2020 were included.Findings8397 eligible with a median age 50 (IQR 43–56). 0·2% (15/8397) confirmed as...
Dynamic hip screws (DHSs) and proximal femoral nails anti-rotation (PFNAs) are well-documented implants for stable intertrochanteric femur fractures(IFFs); however, there is no consensus regarding which type of implant the better option IFFs. This study aimed to compare DHSs with PFNAs in management fractures. A retrospective was performed our institution. Between June, 2005 November, 2015, 267 patients (267 hips) IFFs (AO/OTA Type 3.1A1) were treated a DHS or PFNA. Inclusion exclusion...
The purpose of this study was to evaluate whether PFNA-II (Asia proximal femoral nail anti-rotation) and DHS (dynamic hip screw) carry substantial post-operative hidden blood loss compare with in terms elderly high-risk patients intertrochanteric femur fractures(IFFs). clinical data from Jan 2005 Apr 2015 186 177 were analyzed retrospectively. Indexes including pre- routine, intra- transfusion situation analyzed. perioperative (visible hidden) assessed. intra-operative the group 34.7 ± 2.5...
Breast cancer is the most prevalent malignancy among women. Doxorubicin (Dox) resistance was one of major obstacles to improving clinical outcome breast patients. The purpose this study investigate relationship between FABP signaling pathway and Dox in cancer. property MCF-7/ADR cells evaluated employing CCK-8, Western blot (WB), confocal microscopy techniques. glycolipid metabolic properties MCF-7 were identified using transmission electron microscopy, PAS, Oil Red O staining. FABP5 CaMKII...
1028 Background: RC48-ADC is a novel HER2-targeting antibody–drug conjugate (ADC) that selectively delivers anticancer agent MMAE into HER2-overexpressing tumor cells. A Phase I study (NCT02881138) has preliminary demonstrated well tolerated and clear clinical activity in patients (pts) with metastatic breast cancer (MBC). Methods: This was phase Ib, open-label, multicenter 3 dose cohorts (1.5, 2.0 2.5mg/kg, Q2W). Eligible pts (18-70 years) were assessed HER2-positive (IHC 2+/FISH +, or IHC...
can be considered during the neoadjuvant treatment in all patients who qualify for single-targeted therapy. 2 The KRISTINE study (1) confirmed effectiveness and safety of TCbHP regimen treatment, Therefore, is preferred preoperative treatment. 3The NeoSphere (2) that adding pertuzumab to TH could further increase pCR rate HER-2-positive patients.However, above study, surgery was performed after 4 cycles with THP, dualtargeted therapy suspended then continued 3 FEC therapy.The clinical...
Background: To explore the expression level of has_circ_0000615 in peripheral blood samples and evaluate its diagnostic value for breast cancer patients. Methods: The 95 patients who underwent curative surgical resection age-matched healthy volunteers our institutions from September 2019 to November 2020 were systematically collected. plasma was amplified detected by qRT-PCR, correlation clinicopathological characteristics analyzed. Results: Breast had a significantly higher than controls (P...
The aim of this study was to identify the molecular subtypes breast cancer based on chromatin regulator-related genes.
In locally advanced triple-negative breast cancer (TNBC), patients who did not achieve pathologic complete response (non-pCR) after neoadjuvant chemotherapy develop rapid tumor metastasis. Tumor mutation burden (TMB) is a potential biomarker of therapy, though whether it applicable to TNBC still unclear.A total 14 non-pCR were enrolled, and tissue samples from radical operation collected. Of these, 7 cases developed disease progression within 12 months [short disease-free survival (short...
Abstract According to GLOBOCAN 2012, age-standardized incidence rate (ASIR) of cervical cancer in developed and less countries is 9.9 vs. 15.7 per 100,000 population year. This disparity related inequity access screening. Urban rural screening similar China. We aim assess urban ASIR. Using population-based tumor registration data collected by us Shijiazhuang city (with available for 1,217,437 women 2012) Shexian County 197,416 since 2000), we compared ASIR between the two populations 2012....
Background There are few studies on young patients with metastatic breast cancer (MBC). This study aims to explore the metastasis pattern and prognosis of MBC. Methods A total 6,336 MBC diagnosed in Surveillance, Epidemiology, End Results (SEER) database from 2010 2015 were selected. They divided into two age groups: younger group (≤40 years old) older (>40 old). χ 2 test was used compare clinicopathological characteristics. Survival differences compared by Kaplan–Meier analysis. Cox...
Abstract Background: FS-1502 is a HER2-targeting antibody drug-conjugate with cleavable β-glucuronide linker and an antimitotic agent (monomethyl auristatin F) which showed promising antitumor activity in preclinical studies. We are evaluating the safety tolerability of patients HER2-expressing advanced solid tumors (NCT03944499). Methods: Patients HER2-expresssing who had failed prior standard care therapies were enrolled single-arm, open-label, dose-escalation phase Ia study China. was...